Citation

Hergenroeder G, Redell JB, Moore AN, Dubinsky WP, Funk RT, Crommett JW, Clifton GL, Levine R, Valadka A, Dash PK. J. Neurotrauma 2008; 25(2): 79-93.

Affiliation

Vivian L. Smith Center for Neurologic Research, University of Texas Medical School, Houston, TX, USA.

Copyright

(Copyright © 2008, Mary Ann Liebert Publishers)

DOI

10.1089/neu.2007.0386

PMID

18260791

Abstract

Brain injury biomarkers may have clinical utility in stratifying injury severity level, predicting adverse secondary events or outcomes, and monitoring the effectiveness of therapeutic interventions. As a biomarker source, serum offers several advantages over cerebrospinal fluid (CSF), including ease of accessibility and reduced risk to the patient. We screened pooled serum samples obtained from 11 severely injured traumatic brain injury (TBI) patients (Glasgow Coma Scale [GCS] 25 mm Hg). Our results support the use of serum as a source for discovery of TBI biomarkers, and indicate that serum biomarkers may have utility for predicting secondary pathologies (e.g., elevated ICP) associated with TBI.

Language: en